Enterome Initiates Strategic Expansion With the Opening of US Office in Cambridge, MA

PARIS and CAMBRIDGE, Massachusetts, May 19, 2016 /PRNewswire/ --

ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce that it has opened a new office in Cambridge, MA to support its operations and corporate development activities in the US.

The office is located at Kendall Square, the heart of Boston's booming biotechnology industry, well-known as the global hub for transforming scientific insights into new drugs. The new office brings Enterome closer to its existing partners in the US and provides opportunities to reinforce and extend its scientific expertise and network to develop its business further.

Rodolphe Clerval, Enterome's Chief Business Officer, will head up the US office, and expects to expand the operation over the coming years.

Mr. Clerval said: "Enterome has made great progress leveraging its expertise to unlock the microbiome and identify exciting opportunities to improve the treatment of serious diseases. We have established several partnerships and strong relationships in the US with companies and clinicians at leading research institutions. By starting operations in one of the most vibrant life sciences hubs in the world, we can leverage on these relationships and advance the development of Enterome."

Enterome currently has partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.

About Enterome:  

Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.

The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €32 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and strategic investors (Nestlé Health Science, Shire & INRA transfer).

Additional information about Enterome is available through its website: http://www.enterome.com

Contact: 

Pierre Belichard, CEO
+33 1 75 77 27 87

David Dible / Mark Swallow, Citigate Dewe Rogerson
+44 207 282 2949 / +44 207 282 2948
[email protected]

SOURCE Enterome Bioscience SA